ethyl 3-(5-chloro-2-hydroxybenzoyl)-1-cyano-6,7,12,12b-tetrahydro-indolo[2,3-a]quinolizine-12b-carboxylate | 1415753-39-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 3-(5-chloro-2-hydroxybenzoyl)-1-cyano-6,7,12,12b-tetrahydro-indolo[2,3-a]quinolizine-12b-carboxylate
• 英文别名: ethyl 3-(5-chloro-2-hydroxybenzoyl)-1-cyano-7,12-dihydro-6H-indolo[2,3-a]quinolizine-12b-carboxylate
• CAS: 1415753-39-7
• 化学式: C₂₆H₂₀ClN₃O₄
• 分子量: 473.915
• InChiKey: HORMPQJPMYAJKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• SUBSTITUTED INDOLO [2,3-A] QUINOLIZINES
  申请人：Waldmann Herbert

  公开号：US20120316192A1

  公开（公告）日：2012-12-13

  The present invention relates to novel substituted indolo[2,3-a]quinolizines and stereoisomeric forms thereof and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted indolo[2,3-a]quinolizines together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted indolo[2,3-a]quinolizines have been identified as useful for the prophylaxis and treatment of cancer by the induction of strong mitotic delays, chromosomal misalignments and mitotic tri- and multipolarization leading to cell cycle stop and apoptosis. Furthermore a synthesis for preparation of the substituted indolo[2,3-a]quinolizines is disclosed in the present invention.

  本发明涉及新型的取代吲哚[2,3-a]喹诺里嗪及其立体异构体和/或这些化合物的药用可接受盐，以及包含至少一种这些取代吲哚[2,3-a]喹诺里嗪的药物组合物，以及药用可接受的载体、辅料和/或稀释剂。所述新型取代吲哚[2,3-a]喹诺里嗪已被确认为通过诱导强烈的有丝分裂延迟、染色体错位和有丝分裂三极和/或多极化导致细胞周期停止和凋亡，用于癌症的预防和治疗的有用物质。此外，本发明还公开了取代吲哚[2,3-a]喹诺里嗪的合成方法。
• Substituted indolo [2,3-a] quinolizines in the treatment of cancer
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2532664A1

  公开（公告）日：2012-12-12

  The present invention relates to novel substituted indolo [2,3-a] quinolizines of the general formula (I) and stereoisomeric forms thereof and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted indolo [2,3-a] quinolizines together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted indolo [2,3-a] quinolizines have been identified as useful for the prophylaxis and treatment of cancer by the induction of strong mitotic delays, chromosomal misalignments and mitotic tri- and multipolarization leading to cell cycle stop and apoptosis. Furthermore a synthesis for preparation of the substituted indolo [2,3-a] quinolizines is disclosed in the present invention.

  本发明涉及新颖的取代吲哚[2,3-a]喹啉化合物，其一般式为(I)，以及其立体异构体和/或这些化合物的药学上可接受的盐，以及含有至少一种这些取代吲哚[2,3-a]喹啉的药物组合物，其中还包括药学上可接受的载体、赋形剂和/或稀释剂。所述的新颖取代吲哚[2,3-a]喹啉已被确定为用于预防和治疗癌症的有用药物，通过诱导强烈的有丝分裂延迟、染色体错位和有丝分裂三价和多价化导致细胞周期停滞和凋亡。此外，本发明还公开了一种用于制备取代吲哚[2,3-a]喹啉的合成方法。